Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
Sanfilippo R, Hayward RL, Musoro J, Benson C, Leahy MG, Brunello A, Blay JY, Steeghs N, Desar IME, Ali N, Hervieu A, Thway K, Marreaud S, Litiere S, Kasper B. Sanfilippo R, et al. Among authors: musoro j. JAMA Oncol. 2022 Oct 1;8(10):1420-1425. doi: 10.1001/jamaoncol.2022.3218. JAMA Oncol. 2022. PMID: 35980618 Free PMC article.
Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT).
Stadler R, Romero PO, Bagot M, Quaglino P, Guenova E, Jonak C, Papadavid E, Stranzenbach R, Sartori D, Musoro JZ, Falato C, Marreaud S, Scarisbrick JJ, Knobler R. Stadler R, et al. Eur J Cancer. 2021 Oct;156 Suppl 1:S22-S23. doi: 10.1016/S0959-8049(21)00668-7. Eur J Cancer. 2021. PMID: 34649647 No abstract available.
Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.
Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dirven L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Sloan J, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium (SISAQOL). Pe M, et al. Among authors: musoro jz. Lancet Oncol. 2018 Sep;19(9):e459-e469. doi: 10.1016/S1470-2045(18)30418-2. Lancet Oncol. 2018. PMID: 30191850 Free article.
Quality of life of long-term childhood acute lymphoblastic leukemia survivors: Comparison with healthy controls.
Chantziara S, Musoro J, Rowsell AC, Sleurs C, Coens C, Pe M, Suciu S, Kicinski M, Missotten P, Vandecruys E, Uyttebroeck A, Dresse MF, Pluchart C, Ferster A, Freycon C, Bosch JVWT, Rohrlich P, Benoit Y, Darlington AS, Piette C; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QLG) and Children's Leukemia Group (CLG). Chantziara S, et al. Among authors: musoro j. Psychooncology. 2022 Dec;31(12):2159-2168. doi: 10.1002/pon.6060. Epub 2022 Nov 22. Psychooncology. 2022. PMID: 36307941 Free PMC article.
Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials.
Gamper EM, Musoro JZ, Coens C, Stelmes JJ, Falato C, Groenvold M, Velikova G, Cocks K, Flechtner HH, King MT, Bottomley A; EORTC Genito-Urinary Tract Cancer Group and Quality of Life Groups. Gamper EM, et al. BMC Cancer. 2021 Oct 7;21(1):1083. doi: 10.1186/s12885-021-08609-7. BMC Cancer. 2021. PMID: 34620124 Free PMC article.
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures.
Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck RM, Fitzgerald K, Galinsky J, Giesinger JM, Holzner B, Le Cessie S, O'Connor D, Oliver K, Pawar V, Quinten C, Schlichting M, Ren J, Roychoudhury S, Taphoorn MJB, Velikova G, Wintner LM, Griebsch I, Bottomley A; SISAQOL-IMI Consortium. Pe M, et al. Lancet Oncol. 2023 Jun;24(6):e270-e283. doi: 10.1016/S1470-2045(23)00157-2. Lancet Oncol. 2023. PMID: 37269858 Free article. Review.
Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.
Musoro JZ, Bottomley A, Coens C, Eggermont AM, King MT, Cocks K, Sprangers MA, Groenvold M, Velikova G, Flechtner HH, Brandberg Y; EORTC Melanoma Group and EORTC Quality of Life Group. Musoro JZ, et al. Eur J Cancer. 2018 Nov;104:169-181. doi: 10.1016/j.ejca.2018.09.005. Epub 2018 Oct 22. Eur J Cancer. 2018. PMID: 30359910 Free article.
Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy.
Musoro JZ, Sodergren SC, Coens C, Pochesci A, Terada M, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A; EORTC Quality of Life, Gastro-intestinal Groups. Musoro JZ, et al. Colorectal Dis. 2020 Dec;22(12):2278-2287. doi: 10.1111/codi.15295. Epub 2020 Aug 28. Colorectal Dis. 2020. PMID: 32767619 Free article.
31 results